Drugs / IxCell hUC-MSC-O
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06716281 | Jan 2024 → Dec 2025 overdue | osteoarthritis, knee | Shanghai IxCell Biotechnology Co., LTD | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IxCell hUC-MSC-O | “a single intra-articular injection of IxCell hUC-MSC-O at a dose of 5.0×10\^7 cells” NCT06716281 ↗ |
| Route | Other | “a single intra-articular injection of IxCell hUC-MSC-O” NCT06716281 ↗ |